Answers are grounded in this paper and cite their sources.
Collismycins suffer from limited structural diversity that restricts bioactivity exploration. Herein, we develop a bio-chemo-relay strategy combining biosynthetic engineering and chemical diversification to construct diverse collismycin analogues, affording a potent acetylcholinesterase inhibitor 4h with superior activity to galantamine.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: